We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Nirogacestat

News List

Future Directions and Challenges to Desmoid Tumors and Nirogacestat David Orchard-Webb
January 07, 2025
Desmoid tumors, also known as aggressive fibromatosis, are uncommon non-metastatic soft tissue tumors distinguished by the proliferation of fibroblasts and myofibroblasts.
SpringWorks, Janssen to Evaluate Nirogacestat with Teclistamab for Multiple Myeloma americanpharmaceuticalreview
September 21, 2020
SpringWorks Therapeutics has entered into a clinical collaboration and supply agreement with Janssen Biotech to evaluate SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody ...
SpringWorks Therapeutics in pact with Janssen to assess Nirogacestat with Teclistamab in patients with relapsed or refractory multiple myeloma expresspharma
September 15, 2020
Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities.
EC Grants Orphan Drug Designation for Nirogacestat for Soft Tissue Sarcoma americanpharmaceuticalreview
September 25, 2019
SpringWorks Therapeutics announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft tissue sarcoma.